Веков, Т. Социална фармация и фармацевтично законодателство. Учебник. Издателство на МУ-Плевен, 2014.
AESGP. The Economic and Public Health Value of Self-Medication. Brussels; 2004.
Aronson, JK. From prescription-only to over-the-counter medicines (`PoM to P'): Time for an intermediate category. Br Med Bull. 2009;90(1):63-9.
Black, N. Why we need observational studies to evaluate the effectiveness
of health care. BMJ. 1996; 12(7040):1215-1218.
Bond, C. The over-the-counter pharmaceutical market - policy and practice.
Eurohealth (Lond). 2008;14(3).
Burstein, A. Anatomy of a successful Rx-to-OTC switch. Med Mark Media.
;29(6):10-2.
Calvery, HO, Klumpp TG. The toxicity for human beings of diethylene glycol with sulfanilamide. South Med J. 1939;32:1105-9.
D'Agostino, RB, D'Agostino, RB. Estimating treatment effects using observational
data. JAMA. 2007;297(3):314-6.
Enns T, Damm K, Graf von der Schulenburg. Freier Preiswettbewerb auf dem deutschen OTC-Markt ... PharmacoEconomics Ger Res Artic. 2011;9(1):3-10
Feldman, M. Pros and cons of over-the-counter availability of histamine2-
receptor antagonists. Arch Intern Med. 1993;153(21):2415-24.
Gossel T. Implications of the reclassification of drugs from prescriptiononly
to over-the-counter status. Clin Ther. 1991;13(2):200-15; discus 199.
Hanks, GW. Nonprescription analgesics: a review of acetylsalicylic acid,
paracetamol, and phenacetin. Excerpta Medica; 1983.
Hlatky, M et al. Tying clinical research to patient care by use of an observational
database. Statistics in Medicine. 1984;3(4):375-384.
Hodgson R et al. Measurement of long-term outcomes in observational
and randomised controlled trials. Br J of Psychiatry. 2007;50.suppl:78-84.
Jacobs, LR. Prescription to over-the-counter drug reclassification. Am Fam
Physician. 1998;57(9):2209-14.
Juhl, RP. Prescription to over-the-counter switch: a regulatory perspective.
Clin Ther. 1998;20 Suppl C:C111-7.
Katzung, BG. Basic & Clinical Pharmacology [Internet]. Lange Medical
Books/McGraw Hill; 2004.
Mahecha, LA. Rx-to-OTC switches: trends and factors underlying success.
Nat Rev Drug Discov. 2006;5(5):380-5.
Pawaskar M, Balkrishnan R. Switching from prescription to over-the counter
medications: a consumer ... Manag Care Interface. 2007;20(1):42-7
Palumbo, FB. The impact of the Rx to OTC switch on practicing pharmacists.
Am Pharm. 1991;NS31(4):41-4.
Pray, WS, Worthen DB. A History of Nonprescription Product Regulation.
Taylor&Francis; 2003.
Rosenau, P. Medical Care Review. Health Administration Press; 1994.
Shiffman S, Gitchell J, Pinney J, Burton SL, et al. Public health benefit of
over-the-counter nicotine medications. Tob Control. 1997;21;6(4):306-10
Shiffman S, Sweeney C. Ten years after the Rx-to-OTC switch of nicotine
replacement therapy: what have we ...? Health Policy. 2008;86(1):17-26
Soller, RW. Evolution of self-care with over-the-counter medications. Clin
Ther [Internet]. Elsevier; 1998;19(20):C134-40.
Soller, RW. The Over-the-Counter Scientific/Regulatory Paradigm. Drug
Inf J. 1999;33(3):799-804.
Soller, R. Prescription-to-Over-the-Counter Switch Criteria. Drug Inf J.
;36:309-318.
Sullivan PW. Switching prescription drugs to over the counter: Consumers
may benefit financially in examples from the US. Br Med J. 2005; 330
(7496):904-5.
Synder, K. Rising tide - New wave of Rx-to-OTC switches coming. Drug
Topics. 1995;207:47-9.
Tasch, RF, Goeree R, Henke CJ, O`Brien BJ. Switching the histamine H2
receptor antagonist famotidine to nonprescription status in Canada. An
economic evaluation. Pharmacoeconomics. 1996;9(1):61-75.
Tisman, A. The Rising Tide of OTC in Europe: Trends, Challenges and
New Potential in a Rapidly Evolving Market. 2010;
USCHC. FDA`s Prescription to Over-the-counter Drug Switch: Hearing
Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-eighth Congress, First Session on the Food and Drug Admin. U.S. Gov Printing,1983.
Wax, PM. Elixirs, diluents, and the passage of the 1938 Federal Food,
Drug and Cosmetic Act. Ann Intern Med. 1995;122(6):456-61.
WHO. Guidelines for the Regulatory Assessment of Medicinal Products for Use in Self-medication. World Health Organization; 2000.
www.wsmi.org;
www.ecigintelligence.com
